Bedside Diagnostics ARTIDIS offers a bedside nanomechanical tissue analysis device and holistic data platform, enabling real-time tissue characterization at the point of care. Target customers are hospitals and oncology centers, especially breast cancer programs and multi-center cancer networks. The value proposition includes faster decision-making, potential to reduce dependence on central labs, and support for therapy optimization in chemotherapy, immunotherapy, and cell therapies. With ANGEL trial scale (2,700+ participants) and ongoing multicenter studies, there is market credibility to drive hospital adoptions and service contracts.

Pharma Collaboration The combination of nanomechanical biomarkers and an AI-enabled data platform can accelerate drug discovery and precision oncology. This supports companion diagnostics development, patient stratification, and real-world data generation for clinical trials. The ANGEL study demonstrates capacity for large, multicenter data collection, offering co-development or data licensing opportunities with pharma partners, especially for solid tumors.

Strategic Partnerships Existing collaborations with Hospital Clínic de Barcelona and University of Barcelona provide a proof-of-concept base and clinical validation, easing procurement discussions with hospital networks. The company can leverage these relationships to expand into Europe and North America, particularly targeting NSCLC and breast cancer pathways where their AFM-based diagnostics have shown potential.

Leadership and Funding High-profile board and leadership appointments, including Julie Gerberding as CEO, coupled with 27 million in funding and revenue in the low-to-mid single digits, signal capacity to engage large enterprise customers, pursue partnerships, and negotiate scale deals. This can be positioned in sales pitches as credibility for long-term collaboration and risk-sharing contracts.

Technology Advantage ARTIDIS differentiates with a nanomechanical tissue signature device plus a holistic AI-driven data platform using technologies like PyTorch, OpenAI, and cloud-based analytics. This enables integration with hospital IT systems and EMRs, offering decision-support, analytics, and potential analytics-as-a-service for oncology programs. There is a cross-sell path to hospital IT and oncology data platforms.